Developing a new treatment for non-small cell lung cancer using a targeted antibody
Official title: Antitumor potential of AvFc lectibody in non-small cell lung cancer
Funded at University of Louisville · NIH-10717195 · Data updated 2026-11-12
This study is exploring a new treatment for non-small cell lung cancer that uses a special molecule to help the immune system better fight the cancer, and it's currently being tested in animals to see how safe and effective it is before moving on to people.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Louisville NIH-funded |
| Lab location | 1 site (Louisville, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $402,402 |
| NIH project number | 1R21CA282484-01 |
| Project ID | NIH-10717195 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with advanced non-small cell lung cancer who have not responded well to current therapies.
✕Less likely to help
Patients with early-stage non-small cell lung cancer or those with other types of cancer may not benefit from this research.
What this research studies
This research focuses on creating a novel treatment for non-small cell lung cancer (NSCLC) by targeting specific markers on cancer cells. The approach involves using a specially designed molecule called Avaren-Fc (AvFc), which can recognize and bind to high-mannose glycans found on the surface of malignant cells. By enhancing the immune response against these cancer cells, the treatment aims to improve the effectiveness of existing therapies, especially in advanced stages of the disease. The research includes testing the safety and effectiveness of AvFc in various animal models to gather data before potential human trials.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment option for patients with advanced non-small cell lung cancer.
How similar studies have gone: Other research has shown promise in using targeted immunotherapy approaches for cancer treatment, indicating potential success for this novel method.
Where this research is happening
-
University of Louisville
Louisville, United States Active
Researchers
- Principal investigator: Matoba, Nobuyuki — University of Louisville
- Study coordinator: Matoba, Nobuyuki
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.